127 related articles for article (PubMed ID: 7815310)
1. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration.
Cardot JM; Lefèvre GY; Godbillon JA
J Pharmacokinet Biopharm; 1994 Apr; 22(2):147-56. PubMed ID: 7815310
[TBL] [Abstract][Full Text] [Related]
2. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.
Bichler J; Fichtl B; Siebeck M; Fritz H
Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
Bichler J; Siebeck M; Fichtl B; Fritz H
Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
[TBL] [Abstract][Full Text] [Related]
5. The pharmacology of recombinant hirudin, a new anticoagulant.
Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic studies with recombinant hirudin in dogs.
Nowak G; Markwardt F; Fink E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, ELISA, and radioisotope assays.
Jiang SY; Jiao J; Zhang TT; Xu YP
PLoS One; 2013; 8(6):e64336. PubMed ID: 23785400
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of recombinant hirudin in healthy horses.
Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
10. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
[TBL] [Abstract][Full Text] [Related]
11. Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).
Close P; Bichler J; Kerry R; Ekman S; Bueller HR; Kienast J; Marbet GA; Schramm W; Verstraete M
Coron Artery Dis; 1994 Nov; 5(11):943-9. PubMed ID: 7719527
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and partial thromboplastin time after intravenous recombinant hirudin variant-2 in rhesus monkeys.
Liu XW; Song HF; Tang ZM; Zhao K; Zhu BZ; Wang LP; Zhang Y
Acta Pharmacol Sin; 2002 Sep; 23(9):842-6. PubMed ID: 12230955
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
[TBL] [Abstract][Full Text] [Related]
15. Alteration of pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after repeated intravenous administration in dogs.
Iyer L; Shavit J; Koza M; Calabria R; Moran S; Fareed J
Thromb Res; 1993 Jan; 69(1):59-70. PubMed ID: 8465275
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.
Marbet GA; Verstraete M; Kienast J; Graf P; Hoet B; Tsakiris DA; Silling-Engelhardt G; Close P
J Cardiovasc Pharmacol; 1993 Sep; 22(3):364-72. PubMed ID: 7504125
[TBL] [Abstract][Full Text] [Related]
18. [Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats].
Zhang YJ; Wang XL; Wu JM; Cheng MX
Zhongguo Zhong Yao Za Zhi; 2007 May; 32(9):801-4. PubMed ID: 17639978
[TBL] [Abstract][Full Text] [Related]
19. Clinico-pharmacological studies with recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J; Vogel G
Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
[TBL] [Abstract][Full Text] [Related]
20. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
